title: Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury.
abstract: BACKGROUND
  A randomized, prospective, multicenter, double-blind, placebo-controlled, phase II clinical trial was performed to determine whether inhibition of leukocyte adherence by administration of monoclonal antibody directed against intercellular adhesion molecule-1 would improve burn wound healing.
  
  
  METHODS
  One hundred ten patients with burn injury ranging from 10% to 30% total body surface area were enrolled. Fifty-six patients received placebo (saline) and 54 patients received murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab). Treatment was initiated within 6 hours of injury. Patients had three distinct partial-thickness wound sites assessed. Laser Doppler flowmetry was used to stratify wounds on the day of injury. Wounds were assessed for healing status on day 21 postburn and categorized as healed, nonhealed, or grafted.
  
  
  RESULTS
  Patients treated with enlimomab had a significantly increased percentage of wounds that healed spontaneously in less than 21 days overall and when stratified by burn wound laser Doppler blood flow readings for those wounds at greatest risk for nonhealing.
  
  
  CONCLUSIONS
  These results support the concept that leukocyte adherence is involved in the pathogenesis of burn wound necrosis and suggest a therapeutic mechanism for modulating the inflammatory response after the burn injury that may improve wound healing.
authors.affiliation: Department of Surgery, University of Texas Medical Branch, Galveston, 77555-1172, USA. wmileski@utmb.edu
authors.forename: William J
authors.initials: WJ
authors.lastname: Mileski
authors.forename: Deborah
authors.initials: D
authors.lastname: Burkhart
authors.forename: John L
authors.initials: JL
authors.lastname: Hunt
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Kagan
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Saffle
authors.forename: David N
authors.initials: DN
authors.lastname: Herndon
authors.forename: David M
authors.initials: DM
authors.lastname: Heimbach
authors.forename: Arnold
authors.initials: A
authors.lastname: Luterman
authors.forename: Roger W
authors.initials: RW
authors.lastname: Yurt
authors.forename: Cleon W
authors.initials: CW
authors.lastname: Goodwin
authors.forename: John
authors.initials: J
authors.lastname: Hansborough
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002056:Burns / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology*; D008297:Male; D016028:Receptors, Leukocyte-Adhesion / Q000037:antagonists & inhibitors*; D012044:Regression Analysis
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016028:Receptors, Leukocyte-Adhesion; C474712:enlimomab; D018799:Intercellular Adhesion Molecule-1